

Afamelanotide for Erythropoietic Protoporphyrria

New England Journal of Medicine

373, 48-59

DOI: [10.1056/nejmoa1411481](https://doi.org/10.1056/nejmoa1411481)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Porphyria Diagnosticsâ€™Part 1: A Brief Overview of the Porphyrias. <i>Current Protocols in Human Genetics</i> , 2015, 86, 17.20.1-17.20.26.	3.5	83
3	Pitfalls in Erythrocyte Protoporphyrin Measurement for Diagnosis and Monitoring of Protoporphyrins. <i>Clinical Chemistry</i> , 2015, 61, 1453-1456.	3.2	29
4	Cutaneous Porphyrias: Causes, Symptoms, Treatments and the Danish Incidence 1989â€“2013. <i>Acta Dermato-Venereologica</i> , 2016, 96, 868-872.	1.3	18
5	Advances in the management of erythropoietic protoporphyria – role of afamelanotide. <i>The Application of Clinical Genetics</i> , 2016, Volume 9, 179-189.	3.0	23
7	Recurrent Photodistributed Skin Eruptions in a Teenage Girl. <i>JAMA Dermatology</i> , 2016, 152, 937.	4.1	0
8	Existing therapies and therapeutic targets for erythropoietic protoporphyria. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 577-589.	0.8	2
9	Novel Treatment Using Cimetidine for Erythropoietic Protoporphyrin in Children. <i>JAMA Dermatology</i> , 2016, 152, 1258.	4.1	22
10	Identification of FECH gene multiple variations in two Chinese patients with erythropoietic protoporphyria and a review. <i>Journal of Zhejiang University: Science B</i> , 2016, 17, 813-820.	2.8	6
11	Protoporphyrin IX in the skin measured noninvasively predicts photosensitivity in patients with erythropoietic protoporphyria. <i>British Journal of Dermatology</i> , 2016, 175, 1284-1289.	1.5	16
12	Influence of meteorological data on sun tolerance in patients with erythropoietic protoporphyria in France. <i>British Journal of Dermatology</i> , 2016, 175, 768-775.	1.5	11
13	Afamelanotide: A Review in Erythropoietic Protoporphyrin. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 179-185.	6.7	23
14	Protoporphyrin IX: the Good, the Bad, and the Ugly. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 267-275.	2.5	155
16	Protoporfiria eritropoy�tica. <i>Piel</i> , 2017, 32, 92-97.	0.0	0
17	Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. <i>Clinical Pharmacokinetics</i> , 2017, 56, 815-823.	3.5	44
18	A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH₂ versus the Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH₂: A Bivalent Advantage. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1262-1278.	3.5	17
19	Update on Trial Registration 11 Years after the ICMJE Policy Was Established. <i>New England Journal of Medicine</i> , 2017, 376, 383-391.	27.0	169
20	Insufficient Evidence of Cimetidine Benefit in Protoporphyrinâ€™Reply. <i>JAMA Dermatology</i> , 2017, 153, 238.	4.1	0
21	Case of late�onset erythropoietic protoporphyria with myelodysplastic syndrome who has homozygous <sc>IVS</sc> 3â€™48C polymorphism in the ferrochelatase gene. <i>Journal of Dermatology</i> , 2017, 44, 651-655.	1.2	3

#	ARTICLE	IF	CITATIONS
22	Patients with erythropoietic protoporphyria have reduced erythrocyte protoporphyrin IX from early in pregnancy. <i>British Journal of Dermatology</i> , 2017, 177, e38-e40.	1.5	6
23	A UV-Independent Topical Small-Molecule Approach for Melanin Production in Human Skin. <i>Cell Reports</i> , 2017, 19, 2177-2184.	6.4	59
24	Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria. <i>JAMA Dermatology</i> , 2017, 153, 789.	4.1	70
25	Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017, 1863, 2414-2435.	3.8	60
26	The melanoma-linked <i>MC1R</i> influences dopaminergic neuron survival. <i>Annals of Neurology</i> , 2017, 81, 395-406.	5.3	41
27	Current challenges in photoprotection. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, S91-S99.	1.2	60
28	Porphyria. <i>New England Journal of Medicine</i> , 2017, 377, 862-872.	27.0	272
29	Osteoporosis in patients with erythropoietic protoporphyria. <i>British Journal of Dermatology</i> , 2017, 177, 1693-1698.	1.5	21
30	Basal Cell Carcinoma in Erythropoietic Protoporphyria: All About Ultraviolet Light?. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 270-271.	1.2	0
31	Design of MC1R Selective β -MSH Analogues with Canonical Amino Acids Leads to Potency and Pigmentation. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 9320-9329.	6.4	17
32	Novel approaches to the design of bioavailable melanotropins. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1023-1030.	5.0	13
34	Case Report of Patient With Erythropoietic Protoporphyria and Basal Cell Carcinoma Diagnoses. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 258-260.	1.2	1
35	Facilitating Clinical Studies in Rare Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1031, 125-140.	1.6	9
36	Erythropoietin signaling regulates heme biosynthesis. <i>ELife</i> , 2017, 6, .	6.0	36
37	Hair cortisol is elevated in patients with erythropoietic protoporphyria and correlates with body mass index and quality of life. <i>British Journal of Dermatology</i> , 2018, 178, 1209-1210.	1.5	2
38	MC4R Agonists: Structural Overview on Antiobesity Therapeutics. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 402-423.	8.7	43
39	Erythropoietic Protoporphyria: Initial Diagnosis With Cholestatic Liver Disease. <i>Pediatrics</i> , 2018, 141, S445-S450.	2.1	8
40	Longitudinal Analysis of Erythrocyte and Plasma Protoporphyrin Levels in Patients with Protoporphyria. <i>Journal of Applied Laboratory Medicine</i> , The, 2018, 3, 213-221.	1.3	3

#	ARTICLE	IF	CITATIONS
41	Porphyrias and photosensitivity: pathophysiology for the clinician. <i>Postgraduate Medicine</i> , 2018, 130, 673-686.	2.0	8
44	Recent Developments in the Diagnosis and Management of Photosensitive Disorders. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 707-731.	6.7	15
45	Oral Photoprotection: Effective Agents and Potential Candidates. <i>Frontiers in Medicine</i> , 2018, 5, 188.	2.6	55
46	Melanotan II causes hypothermia in mice by activation of mast cells and stimulation of histamine 1 receptors. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 315, E357-E366.	3.5	7
47	Photocontact Dermatitis and Its Clinical Mimics: an Overview for the Allergist. <i>Clinical Reviews in Allergy and Immunology</i> , 2019, 56, 32-40.	6.5	24
48	The Biology of Pigmentation. , 2019, , 21-50.		0
49	Old and new tools to study human brain physiology: Current state, future directions and implications for metabolic regulation. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, iii-viii.	3.4	11
50	Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 309-313.	1.1	9
51	Patient empowerment and access to medicines: Insights from a scientist-patient suffering from erythropoietic protoporphyria. <i>Medicine Access Point of Care</i> , 2019, 3, 239920261986516.	1.0	5
52	Clinical Guide and Update on Porphyrias. <i>Gastroenterology</i> , 2019, 157, 365-381.e4.	1.3	101
53	The essential role of the transporter ABCG2 in the pathophysiology of erythropoietic protoporphyria. <i>Science Advances</i> , 2019, 5, eaaw6127.	10.3	25
54	Congenital erythropoietic porphyria: Recent advances. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 288-297.	1.1	45
55	Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 332-341.	1.1	12
56	Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 298-303.	1.1	60
57	Oxygen and Conformation Dependent Protein Oxidation and Aggregation by Porphyrins in Hepatocytes and Light-Exposed Cells. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 8, 659-682.e1.	4.5	19
58	Current and innovative emerging therapies for porphyrias with hepatic involvement. <i>Journal of Hepatology</i> , 2019, 71, 422-433.	3.7	24
59	Photocutaneous Porphyrias. <i>Current Dermatology Reports</i> , 2019, 8, 52-62.	2.1	4
60	Erythropoietic Protoporphyria in a Japanese Population. <i>Acta Dermato-Venereologica</i> , 2019, 99, 634-639.	1.3	9

#	ARTICLE	IF	CITATIONS
61	Warfarin ineffective as symptomatic therapy for erythropoietic protoporphyria. <i>Australasian Journal of Dermatology</i> , 2019, 60, e360-e361.	0.7	2
62	What's New in Photoprotection. <i>Dermatologic Clinics</i> , 2019, 37, 149-157.	1.7	63
64	Evaluating quality of life tools in North American patients with erythropoietic protoporphyria and X-linked protoporphyria. <i>JIMD Reports</i> , 2019, 50, 9-19.	1.5	15
65	Discovery of a Highly Selective MC1R Agonists Pentapeptide to Be Used as a Skin Pigmentation Enhancer and with Potential Anti-Aging Properties. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6143.	4.1	18
66	Congenital erythropoietic porphyria and erythropoietic protoporphyria: Identification of 7 uroporphyrinogen III synthase and 20 ferrochelatase novel mutations. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 358-362.	1.1	9
67	An Update on Drug-Induced Pigmentation. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 75-96.	6.7	22
68	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , 2019, 125, 18-44.	4.1	29
69	Developing a Biased Unmatched Bivalent Ligand (BUmBL) Design Strategy to Target the GPCR Homodimer Allosteric Signaling (cAMP over I ² -Arrestin 2 Recruitment) Within the Melanocortin Receptors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 144-158.	6.4	19
70	Quality of life and psychological impact in the photodermatoses: a systematic review. <i>British Journal of Dermatology</i> , 2020, 182, 1092-1102.	1.5	27
71	Visible light in photodermatology. <i>Photochemical and Photobiological Sciences</i> , 2020, 19, 99-104.	2.9	45
72	The Patient Perspective: A Matter of Minutes. <i>Patient</i> , 2020, 13, 1-6.	2.7	8
73	Photoprotection of the future: challenges and opportunities. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 447-454.	2.4	46
74	Clinical and molecular epidemiology of erythropoietic protoporphyria in Italy. <i>European Journal of Dermatology</i> , 2020, 30, 532-540.	0.6	10
75	Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 400-410.	2.5	12
77	New drug approvals for 2019: Synthesis and clinical applications. <i>European Journal of Medicinal Chemistry</i> , 2020, 205, 112667.	5.5	36
78	Increased phototoxic burn tolerance time and quality of life in patients with erythropoietic protoporphyria treated with afamelanotide – a three years observational study. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 213.	2.7	17
80	Melanocortin 3 receptor activation with [D-Trp ⁸]- β -MSH suppresses inflammation in apolipoprotein E deficient mice. <i>European Journal of Pharmacology</i> , 2020, 880, 173186.	3.5	9
81	Effects of solar radiation and an update on photoprotection. <i>Anales De Pediatr�a (English Edition)</i> , 2020, 92, 377.e1-377.e9.	0.2	5

#	ARTICLE	IF	CITATIONS
83	Current and emerging treatments targeting the neuroendocrine system for disorders of the skin and its appendages. <i>Experimental Dermatology</i> , 2020, 29, 801-813.	2.9	7
84	Topical treatment strategies to manipulate human skin pigmentation. <i>Advanced Drug Delivery Reviews</i> , 2020, 153, 65-71.	13.7	35
85	Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1517-1519.	1.2	12
86	Mild iron deficiency does not ameliorate the phenotype of a murine erythropoietic protoporphyria model. <i>American Journal of Hematology</i> , 2020, 95, 492-496.	4.1	5
87	Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice. <i>JAMA Dermatology</i> , 2020, 156, 570.	4.1	27
88	Pain, swelling and irritability in the sun: what is the diagnosis?. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2021, 106, 102-106.	0.5	0
89	Incidencia y prevalencia de la protoporfiria eritropoy�tica en Colombia, 2014-2018. <i>Actas Dermo-sifiliogr�ficas</i> , 2021, 112, 186-188.	0.4	0
90	Clinical features of genetic cutaneous porphyrias in Israel: A nationwide survey. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2021, 37, 236-242.	1.5	1
91	Evidence in the UK Biobank for the underdiagnosis of erythropoietic protoporphyria. <i>Genetics in Medicine</i> , 2021, 23, 140-148.	2.4	17
92	Inherited Porphyrias. , 2021, , 373-411.		1
93	Metabolic and Nutritional Disorders Relevant in Dermatology. , 2021, , 1-39.		0
94	Porphyrias. , 2021, , 1-15.		0
95	Disorders of porphyrin metabolism. , 2021, , 503-528.		0
96	Porphyrien. , 2021, , 413-423.		0
97	Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 151-160.	3.1	23
98	Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide. <i>Photochemical and Photobiological Sciences</i> , 2021, 20, 315-320.	2.9	3
99	Inherited genetic late�onset erythropoietic protoporphyria: A systematic review of the literature. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2021, 37, 374-379.	1.5	2
100	Incidence and Prevalence of Erythropoietic Protoporphyria in Colombia Between 2014 and 2018. <i>Actas Dermo-sifiliogr�ficas</i> , 2021, 112, 186-188.	0.4	0

#	ARTICLE	IF	CITATIONS
101	Heme Biosynthesis and the Porphyrins in Children. , 2021, , 530-547.		0
103	Peptide-Based Strategies for Targeted Tumor Treatment and Imaging. <i>Pharmaceutics</i> , 2021, 13, 481.	4.5	31
105	The melanocortin-3 receptor is a pharmacological target for the regulation of anorexia. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	31
106	Erythropoietic protoporphyria: time to prodrome, the warning signal to exit sun exposure without painâ€”a patient-reported outcome efficacy measure. <i>Genetics in Medicine</i> , 2021, 23, 1616-1623.	2.4	10
107	Photoprotection according to skin phototype and dermatoses: practical recommendations from an expert panel. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1460-1469.	2.4	77
108	Porphyria: awareness is the key to diagnosis!. <i>Acta Clinica Belgica</i> , 2022, 77, 703-709.	1.2	5
109	Visible light. Part I: Properties and cutaneous effects of visible light. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1219-1231.	1.2	76
110	Visible light. Part II: Photoprotection against visible and ultraviolet light. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1233-1244.	1.2	52
111	Significance of Heme and Heme Degradation in the Pathogenesis of Acute Lung and Inflammatory Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5509.	4.1	18
113	Clinical and biochemical footprints of inherited metabolic diseases. VI. Metabolic dermatoses. <i>Molecular Genetics and Metabolism</i> , 2021, 134, 87-95.	1.1	10
114	NDP-MSH treatment recovers marginal lungs during ex vivo lung perfusion (EVLV). <i>Peptides</i> , 2021, 141, 170552.	2.4	12
115	Development of hMC1R Selective Small Agonists for Sunless Tanning and Prevention of Genotoxicity of UV in Melanocytes. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1819-1829.	0.7	12
116	Behind the Scene: Exploiting MC1R in Skin Cancer Risk and Prevention. <i>Genes</i> , 2021, 12, 1093.	2.4	15
117	Hematopoietic stem cell transplant for erythropoietic porphyrias in pediatric patients. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29231.	1.5	9
118	MC1R Functions, Expression, and Implications for Targeted Therapy. <i>Journal of Investigative Dermatology</i> , 2022, 142, 293-302.e1.	0.7	25
119	NNT mediates redox-dependent pigmentation via a UVB- and MITF-independent mechanism. <i>Cell</i> , 2021, 184, 4268-4283.e20.	28.9	35
120	Expert consensus statement on acute hepatic porphyria in Belgium. <i>Acta Clinica Belgica</i> , 2022, 77, 735-741.	1.2	5
121	Repurposing of glycine transport inhibitors for the treatment of erythropoietic protoporphyria. <i>Cell Chemical Biology</i> , 2021, 28, 1221-1234.e6.	5.2	7

#	ARTICLE	IF	CITATIONS
122	Porphyrias in the Age of Targeted Therapies. <i>Diagnostics</i> , 2021, 11, 1795.	2.6	8
123	Porphyrias: Acute Manifestations. <i>Contemporary Endocrinology</i> , 2021, , 239-256.	0.1	0
124	Sunscreen-Based Skin Protection Against Solar Insult: Molecular Mechanisms and Opportunities. , 2019, , 377-404.		3
125	Modelling the ferrochelatase c.315-48C modifier mutation for erythropoietic protoporphyria (EPP) in mice. <i>DMM Disease Models and Mechanisms</i> , 2017, 10, 225-233.	2.4	9
126	An overview of the cutaneous porphyrias. <i>F1000Research</i> , 2017, 6, 1906.	1.6	27
127	Iron Hack - A symposium/hackathon focused on porphyrias, Friedreichâ€™s ataxia, and other rare iron-related diseases. <i>F1000Research</i> , 2019, 8, 1135.	1.6	11
128	Structures of active melanocortin-4 receptorâ€™Gs-protein complexes with NDP-Î±-MSH and setmelanotide. <i>Cell Research</i> , 2021, 31, 1176-1189.	12.0	40
129	Metabolic and Nutritional Disorders Relevant in Dermatology. , 2022, , 547-584.		1
130	Disorders of Haem Biosynthesis. , 2016, , 515-527.		0
131	Porphyrias: Diagnosis and Management. , 2016, , 23-28.		0
132	Photosensitivity and Photoreaction. , 2017, , 361-375.		0
133	Neue Arzneimittel 2016. , 2017, , 55-135.		0
134	Medikamentenpreise: hoffnungslos?. <i>Pharma-Kritik (discontinued)</i> , 2017, 38, .	0.0	0
135	The Biology of Pigmentation. , 2018, , 1-30.		1
136	Porphyrien. , 2018, , 1-16.		0
137	Melanoma Prevention and Screening. , 2019, , 1-46.		1
138	The porphyrias. , 2020, , 2032-2054.		0
139	Melanoma Prevention and Screening. , 2020, , 525-570.		4

#	ARTICLE	IF	CITATIONS
140	ABCB6 Polymorphisms are not Overly Represented in Patients with Porphyrria. <i>Blood Advances</i> , 2021, , .	5.2	2
141	Melanogenic effect of dersimelagon (MTâ€7117), a novel oral melanocortin 1 receptor agonist. <i>Skin Health and Disease</i> , 0, , e78.	1.5	11
142	Beyond pigmentation: signs of liver protection during afamelanotide treatment in Swiss patients with erythropoietic protoporphyria, an observational study. <i>Therapeutic Advances in Rare Disease</i> , 2021, 2, 263300402110654.	0.7	1
143	Challenges in Treating Genodermatoses: New Therapies at the Horizon. <i>Frontiers in Pharmacology</i> , 2021, 12, 746664.	3.5	6
144	The Porphyrrias. , 2022, , 1910-1914.		0
145	Recognized and Emerging Features of Erythropoietic and X-Linked Protoporphyria. <i>Diagnostics</i> , 2022, 12, 151.	2.6	9
146	Objective light exposure measurements and circadian rhythm in patients with erythropoietic protoporphyria: A case-control study. <i>Molecular Genetics and Metabolism</i> , 2022, 135, 215-220.	1.1	3
148	Melanocortin-1 receptor mutations and pigmentation: Insights from large animals. <i>Progress in Molecular Biology and Translational Science</i> , 2022, , .	1.7	7
149	Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinsonâ€™s disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 16.	10.8	8
150	The Porphyrrias. <i>JDDG - Journal of the German Society of Dermatology</i> , 2022, 20, 316-331.	0.8	2
151	Die Porphyrrien. <i>JDDG - Journal of the German Society of Dermatology</i> , 2022, 20, 316-333.	0.8	0
153	Cimetidine for erythropoietic protoporphyria. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 38, 102793.	2.6	5
154	In vitro Assessment of Solar Filters for Erythropoietic Protoporphyria in the Action Spectrum of Protoporphyrin IX. <i>Frontiers in Medicine</i> , 2021, 8, 796884.	2.6	2
155	Attenti al sole e pensa al fegato: due casi pediatrici di protoporfiria eritropoietica. <i>Medico E Bambino Pagine Elettroniche</i> , 2020, 23, 149-152.	0.0	0
156	Porphyrias. , 2022, , 1691-1705.		0
157	â€ they had interpreted â€disabilityâ€ as referring to a patently visible disabilityâ€™: experience of a patient group with NICE. <i>Disability and Society</i> , 0, , 1-7.	2.2	2
158	Psychological Aspect and Quality of Life in Porphyrrias: A Review. <i>Diagnostics</i> , 2022, 12, 1193.	2.6	4
159	Ferrochelataze: Mapping the Intersection of Iron and Porphyrin Metabolism in the Mitochondria. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	3.7	13

#	ARTICLE	IF	CITATIONS
160	Diagnosis and treatment of icteric hepatitis caused by erythropoietic protoporphyria A case report. <i>Liver Research</i> , 2022, , .	1.4	0
162	Mass Spectrometry Approaches Empowering Neuropeptide Discovery and Therapeutics. <i>Pharmacological Reviews</i> , 2022, 74, 662-679.	16.0	5
163	Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 1827-1845.	4.3	12
166	Clinical and preclinical data on therapeutic peptides. , 2022, , 657-688.		0
167	Evidence-based consensus guidelines for the diagnosis and management of erythropoietic protoporphyria and X-linked protoporphyria. <i>Journal of the American Academy of Dermatology</i> , 2023, 89, 1227-1237.	1.2	7
168	Late-Stage Functionalization with Cysteine Staples Generates Potent and Selective Melanocortin Receptor-1 Agonists. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 12956-12969.	6.4	4
169	Discovery of novel N-(1-benzyl-1H-imidazol-2-yl)amide derivatives as melanocortin 1 receptor agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, , 129040.	2.2	0
170	Association of quality of life measures with afamelanotide treatment in patients with erythropoietic protoporphyria and x-linked protoporphyria: A retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 880-882.	1.2	1
171	Experimental and approved treatments for skin photosensitivity in individuals with erythropoietic protoporphyria or X-linked protoporphyria: A systematic review. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114132.	5.6	6
173	Erythropoietic protoporphyria in the Netherlands: Clinical features, psychosocial impact and the effect of afamelanotide. <i>Journal of Dermatology</i> , 2023, 50, 445-452.	1.2	2
174	Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016â€“2020): A Recapitulation of Chirality. <i>Pharmaceuticals</i> , 2023, 16, 339.	3.8	4
175	The Oral Bioavailability and Effect of Various Gastric Conditions on the Pharmacokinetics of Dersimelagon in Healthy Adult Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2023, 12, 493-501.	1.6	2
176	Treatment update for vitiligo based on autoimmune inhibition and melanocyte protection. <i>Expert Opinion on Therapeutic Targets</i> , 2023, 27, 189-206.	3.4	0
177	Quality-Adjusted Life Years in Erythropoietic Protoporphyria and Other Rare Diseases: A Patient-Initiated EQ-5D Feasibility Study. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 5296.	2.6	2
178	Computational Screening of Approved Drugs for Inhibition of the Antibiotic Resistance Gene <i>mecA</i> in Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Strains. <i>BioTech</i> , 2023, 12, 25.	2.6	2
179	Dersimelagon in Erythropoietic Protoporphyrias. <i>New England Journal of Medicine</i> , 2023, 388, 1376-1385.	27.0	6
180	Phototesting in erythropoietic protoporphyria trials: A systematic review. <i>Experimental Dermatology</i> , 2023, 32, 1042-1047.	2.9	0
181	Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria. <i>Life</i> , 2023, 13, 1066.	2.4	1

#	ARTICLE	IF	CITATIONS
182	Alpha-Melanocyte-Stimulating Hormone-Mediated Appetite Regulation in the Central Nervous System. <i>Neuroendocrinology</i> , 2023, 113, 885-904.	2.5	1
184	Dersimelagon in Erythropoietic Protoporphyrins. <i>New England Journal of Medicine</i> , 2023, 388, 2491-2493.	27.0	0
185	Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics. , 2023, , 108487.		0
186	MC1R Peptide Agonist Self-Assembles into a Hydrogel That Promotes Skin Pigmentation for Treating Vitiligo. <i>ACS Nano</i> , 2023, 17, 8723-8733.	14.6	7
187	Targeting the central melanocortin system for the treatment of metabolic disorders. <i>Nature Reviews Endocrinology</i> , 2023, 19, 507-519.	9.6	4
188	A feasibility and safety study of afamelanotide in acute stroke patients “an open label, proof of concept, phase iia clinical trial. <i>BMC Neurology</i> , 2023, 23, .	1.8	1
189	Update on the Porphyrins. <i>Annual Review of Medicine</i> , 2024, 75, .	12.2	2
190	A Mysterious Abdominal Pain. <i>Gastroenterology</i> , 2024, 166, 27-30.	1.3	0
191	Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects. <i>International Journal of Molecular Sciences</i> , 2023, 24, 12152.	4.1	0
192	The Cutaneous Porphyrins. , 2023, , 797-814.		0
193	Erythropoietic Protoporphyrin and Afamelanotide: A Patient’s Perspective. <i>Clinical and Experimental Dermatology</i> , 0, , .	1.3	0
194	Current trials in erythropoietic protoporphyria: are placebo controls ethical?. <i>Orphanet Journal of Rare Diseases</i> , 2023, 18, .	2.7	0
195	Bitopertin for Erythropoietic Protoporphyrin: A New Paradigm “and New Hope “ for a Rare, Devastating Disease. , 2023, 20, .		0
196	Erythropoietic protoporphyria: case reports for clinical and therapeutic hints. <i>Italian Journal of Pediatrics</i> , 2023, 49, .	2.6	0
197	Development and content validation of a sunlight exposure diary in patients with erythropoietic protoporphyria. <i>Journal of Patient-Reported Outcomes</i> , 2023, 7, .	1.9	1
198	Peripheral MC1R Activation Modulates Immune Responses and is Neuroprotective in a Mouse Model of Parkinson’s Disease. <i>Journal of NeuroImmune Pharmacology</i> , 0, , .	4.1	0
199	lluminating Dersimelagon: A Novel Agent in the Treatment of Erythropoietic Protoporphyrin and X-Linked Protoporphyrin. <i>Pharmaceuticals</i> , 2024, 17, 31.	3.8	0
200	The Rare Diseases Clinical Research Network: a model for clinical trial readiness. <i>Therapeutic Advances in Rare Disease</i> , 2023, 4, .	0.7	0

#	ARTICLE	IF	CITATIONS
201	Skin Protection by Carotenoid Pigments. International Journal of Molecular Sciences, 2024, 25, 1431.	4.1	1
202	Treatment strategy for erythropoietic protoporphyria accompanied by severe abdominal pain and liver injury. , 2024, 3, 36-38.		0
203	Development and Content Validation of Novel Patient-Reported Outcome Measures to Assess Disease Severity and Change in Patients with Erythropoietic Protoporphyrin: The EPP Impact Questionnaire (EPIQ). Patient Related Outcome Measures, 0, Volume 15, 17-30.	1.2	0
204	Metal-free photocatalytic cross-electrophile coupling enables C1 homologation and alkylation of carboxylic acids with aldehydes. Nature Communications, 2024, 15, .	12.8	0
205	Congenital Erythropoietic Porphyria: A Rare Inherited Disorder. Cureus, 2024, , .	0.5	0